Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Rhonda Hill

Nurse Practitioner Jonesboro, AR Nurse Practitioner

NPI 1215336474 CMS profile 10638972

300 Carson St, Jonesboro, AR 72401

Open in the dashboard

General payments

$19,874

1,012 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Rhonda Hill of Jonesboro, AR is reported in the CMS Open Payments database as having received $19,874 across 1,012 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 98th percentile of Nurse Practitioner profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $3,976 197
2024 General $4,088 205
2023 General $4,684 215
2022 General $4,895 261
2021 General $2,231 134

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Rhonda Hill
  • Nurse Practitioner median
  • Middle half of Nurse Practitioner
  • National median

In program year 2025, general payments to Rhonda Hill were reported at $3,976. Among 41,044 Nurse Practitioner profiles paid that year, the median was $174 and the middle half received between $55 and $557.

Show as a table
Year Rhonda Hill Nurse Practitioner median Middle half National median
2019 $0 $50 $22–$97 $163
2020 $0 $40 $16–$108 $114
2021 $2,231 $135 $40–$426 $132
2022 $4,895 $152 $48–$470 $149
2023 $4,684 $166 $54–$529 $160
2024 $4,088 $173 $55–$556 $164
2025 $3,976 $174 $55–$557 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. GlaxoSmithKline, LLC. $3,379 171 payments
  2. AstraZeneca Pharmaceuticals LP $2,819 120 payments
  3. Boehringer Ingelheim Pharmaceuticals, Inc. $1,319 91 payments
  4. Amgen Inc. $1,283 74 payments
  5. Regeneron Healthcare Solutions, Inc. $999 35 payments
  6. Jazz Pharmaceuticals Inc. $865 36 payments
  7. Genzyme Corporation $793 32 payments
  8. Genentech USA, Inc. $657 40 payments
  9. Mylan Specialty L.P. $635 36 payments
  10. Takeda Pharmaceuticals U.S.A., Inc. $615 33 payments
  11. Other $6,510 344 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $19,647 1,005 payments
  2. Education $227 7 payments
Products named General payments · program years 2021–2025
  1. TRELEGY ELLIPTA $1,785 112 payments
  2. BREZTRI $1,061 42 payments
  3. NUCALA $896 57 payments
  4. XYWAV $865 36 payments
  5. DUPIXENT Inflammation And Immunology $798 25 payments
  6. DUPIXENT Immunology $793 32 payments
  7. TEZSPIRE $742 24 payments
  8. YUPELRI $700 37 payments
  9. AREXVY $664 24 payments
  10. Xolair $608 37 payments
  11. Other $12,973 729 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 26 drugs

Part D claims

1,972

Median for Nurse Practitioner: 389

Drug cost

$634,410

Median for Nurse Practitioner: $21,885

Branded share of claims

77.4%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 448 $336,420
Breztri Aerosphere Budesonide/Glycopyr/Formoterol Brand 196 $144,567
Breo Ellipta Fluticasone/Vilanterol Brand 85 $36,130
Anoro Ellipta Umeclidinium Brm/Vilanterol Tr Brand 44 $27,566
Spiriva Respimat Tiotropium Bromide Brand 32 $17,807
Albuterol Sulfate Hfa Albuterol Sulfate Brand 467 $12,728
Stiolto Respimat Tiotropium Br/Olodaterol Hcl Brand 25 $11,614
Advair Hfa Fluticasone Propion/Salmeterol Brand 23 $11,438
Symbicort Budesonide/Formoterol Fumarate Brand 31 $8,425
Incruse Ellipta Umeclidinium Bromide Brand 15 $7,774

The 10 drugs with the highest cost, of 26 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 9 billing codes

Paid by Medicare

$41,803

Medicare's payments for the services billed

Medicare patients

621

Average age 72

Services billed

871

337 women, 284 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 55%
COPD 48%
Diabetes 43%
Ischemic heart disease 39%
Depression 32%
Atrial fibrillation 29%
Heart failure 25%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 42 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
DUPIXENT
$401 — —
AREXVY
$340 — —
TRELEGY ELLIPTA
$236 448 —
AIRSUPRA
$229 — —
OFEV
$226 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 42 with Patron

Records

1,012 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner in Arkansas

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record